Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Eshbal Acquires a 55% Interest in Dare to Be Different Foods (click to learn more) CSE: ALEN.U — AI Meets Digital Health (click to learn more) What’s Behind Cannabis Stock HERB? (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Citius Pharmaceuticals Inc CTXR

Healthcare Biotechnology
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company’s late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections... see more

Recent & Breaking News (NDAQ:CTXR)

Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

PR Newswire December 9, 2025

Citius Oncology Expands LYMPHIR(TM) Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim

PR Newswire December 4, 2025

Citius Oncology Announces U.S. Commercial Launch of LYMPHIR(TM), a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)

PR Newswire December 1, 2025

Citius Oncology to Advance Commercial Launch of LYMPHIR(TM) with Verix AI Integration

PR Newswire November 21, 2025

Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

PR Newswire October 21, 2025

Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

PR Newswire October 21, 2025

Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR(TM) Commercial Launch

PR Newswire October 20, 2025

Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences

PR Newswire October 17, 2025

Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR(TM)

PR Newswire October 16, 2025

Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

PR Newswire September 10, 2025

Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

PR Newswire September 9, 2025

Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch

PR Newswire August 22, 2025

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update

PR Newswire August 12, 2025

Citius Oncology Announces Closing of $9.0 Million Public Offering

PR Newswire July 17, 2025

Citius Oncology Announces Pricing of $9.0 Million Public Offering

PR Newswire July 16, 2025

Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

PR Newswire July 8, 2025

Citius Oncology Anticipates Commercial Launch of LYMPHIR(TM) in 2025

PR Newswire June 17, 2025

Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules

PR Newswire June 12, 2025

Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules

PR Newswire June 10, 2025

Citius Oncology Enters into Distribution Services Agreement with Cardinal Health

PR Newswire June 9, 2025

Podcasts